Stockscreener 앱 받기
2.68
4.28%
0.11
시간 외 거래:
2.75
0.07
+2.61%
전일 마감가:
$2.57
열려 있는:
$2.5
하루 거래량:
16.63M
Relative Volume:
1.00
시가총액:
$894.94M
수익:
$32.77M
순이익/손실:
$-440.22M
주가수익비율:
-1.6048
EPS:
-1.67
순현금흐름:
$-400.48M
1주 성능:
-14.38%
1개월 성능:
+54.02%
6개월 성능:
-54.19%
1년 성능:
-67.16%
1일 변동 폭
$2.45
$2.71
1주일 범위
$2.45
$3.41
52주 변동 폭
$1.6385
$12.51
Iovance Biotherapeutics Inc Stock (IOVA) Company Profile
명칭
Iovance Biotherapeutics Inc
전화
(650) 260-7120
주소
825 INDUSTRIAL ROAD, SAN CARLOS
IOVA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
IOVA
Iovance Biotherapeutics Inc
|
2.68 | 858.21M | 32.77M | -440.22M | -400.48M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Iovance Biotherapeutics Inc Stock (IOVA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-15 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-05-16 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-05-12 | 다운그레이드 | Truist | Buy → Hold |
| 2025-05-09 | 다운그레이드 | Citizens JMP | Mkt Outperform → Mkt Perform |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-07-29 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-09-18 | 재확인 | Barclays | Overweight |
| 2023-05-30 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-27 | 재개 | Wells Fargo | Equal Weight |
| 2023-01-27 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-12-09 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-10-31 | 개시 | Guggenheim | Neutral |
| 2022-08-18 | 재개 | Wells Fargo | Equal Weight |
| 2022-01-28 | 업그레이드 | Stifel | Hold → Buy |
| 2021-12-07 | 재개 | Cowen | Outperform |
| 2021-06-10 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2021-05-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-05-19 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2021-05-19 | 다운그레이드 | Stifel | Buy → Hold |
| 2021-05-03 | 개시 | Truist | Buy |
| 2021-04-16 | 개시 | Goldman | Buy |
| 2021-03-08 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2020-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-10-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-04-22 | 개시 | Mizuho | Buy |
| 2020-03-04 | 개시 | Barclays | Overweight |
| 2020-02-26 | 재확인 | H.C. Wainwright | Buy |
| 2020-02-26 | 재확인 | Oppenheimer | Outperform |
| 2019-12-18 | 개시 | JMP Securities | Mkt Outperform |
| 2019-10-01 | 개시 | Stifel | Buy |
| 2019-04-29 | 개시 | Piper Jaffray | Overweight |
| 2019-02-28 | 재확인 | Chardan Capital Markets | Buy |
| 2019-02-07 | 개시 | Robert W. Baird | Outperform |
| 2018-12-31 | 재개 | B. Riley FBR | Buy |
| 2018-07-06 | 재확인 | Chardan Capital Markets | Buy |
| 2018-04-10 | 업그레이드 | B. Riley FBR, Inc. | Neutral → Buy |
| 2018-03-13 | 재확인 | B. Riley FBR, Inc. | Neutral |
| 2018-02-23 | 다운그레이드 | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-01-25 | 재확인 | H.C. Wainwright | Buy |
| 2017-11-01 | 재확인 | B. Riley FBR, Inc. | Buy |
모두보기
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
Is Iovance Biotherapeutics Inc. stock overvalued or undervaluedMarket-leading growth rates - jammulinksnews.com
What are Iovance Biotherapeutics Inc. company’s key revenue driversMassive wealth growth - jammulinksnews.com
Will Iovance Biotherapeutics Inc. price bounce be sustainableFree Early Entry Picks Before News Breakout - Newser
What institutional investors are buying Iovance Biotherapeutics Inc. stockAchieve consistent profits with proven strategies - jammulinksnews.com
What are the latest earnings results for Iovance Biotherapeutics Inc.Invest smarter with actionable trading signals - jammulinksnews.com
What is the dividend policy of Iovance Biotherapeutics Inc. stockStock Market Picks With High Returns - jammulinksnews.com
A Closer Look at Iovance Biotherapeutics Inc (IOVA) Stock Gains - investchronicle.com
Iovance Biotherapeutics: Unlocking TIL Therapy's Potential Amid Funding Challenges - AInvest
Iovance Biotherapeutics (IOVA): Promising TIL Therapy Gains Momentum Amid Funding Challenges - Yahoo Finance
Day 6 of Loss Streak for Iovance Biotherapeutics Stock with -35% Return (vs. -65% YTD) [7/31/2025] - Trefis
Iovance Biotherapeutics (IOVA) Gets Downgraded to Sell from Neutral at Goldman Sachs - MSN
Intraday pattern recognizer results for Iovance Biotherapeutics Inc.Real-Time Setup Summary with ROI Focus - Newser
Iovance Biotherapeutics: Recent Clinical Study Results and Leadership Appointments Boost Growth Prospects - AInvest
Iovance Biotherapeutics shares rise 4.12% premarket after Eisai and Biogen's Alzheimer's drug LEQEMBI shows sustained long-term benefits. - AInvest
Exit strategy if you’re trapped in Iovance Biotherapeutics Inc.Chart Driven Entry Timing for Swing Trades - Newser
What is the risk reward ratio of investing in Iovance Biotherapeutics Inc. stockEarnings Report Planner For 2025 - jammulinksnews.com
Iovance Biotherapeutics Inc. Building a Base Near SupportSwing Trade Entry Alert Analysis - beatles.ru
What moving averages say about Iovance Biotherapeutics Inc.Real Time Growth Signal with Smart Setup - Newser
Day 5 of Loss Streak for Iovance Biotherapeutics Stock with -33% Return (vs. -64% YTD) [7/30/2025] - Trefis
Market Shock Waves: Iovance Biotherapeutics’ Sudden Challenges - timothysykes.com
Iovance Biotherapeutics Faces Market Challenges Amid Financial Setbacks - StocksToTrade
Is Iovance Biotherapeutics Stock Due for a Big Rally? - Mitrade
Using AI based signals to follow Iovance Biotherapeutics Inc.Chart Pattern Recognition for Profit Timing - Newser
Can Iovance Biotherapeutics Inc. rally from current levelsShort-Term Profit Alert With Entry Forecast - newser.com
How to monitor Iovance Biotherapeutics Inc. with trend dashboardsReliable Setup Screener with Low Risk - Newser
Is Iovance Biotherapeutics Inc. Stock a Smart Buy in 2025 Investment Analysis InsideFree Optimized Watchlist With Daily Adjustments - Newser
Published on: 2025-07-29 18:47:39 - beatles.ru
Why Iovance Biotherapeutics Inc. stock attracts strong analyst attentionReal Time Trade Execution Alert Plan - Newser
Iovance Biotherapeutics Inc. Company Revenue and Profit Trends: A Deep DiveWatchlist for Low Risk High Return Stocks Updated - metal.it
Price momentum metrics for Iovance Biotherapeutics Inc. explainedMomentum Prediction Based on AI Backtesting - Newser
Is Iovance Biotherapeutics a Buy on the Dip? Assessing the Risk/Reward of Autologous Cell Therapy Commercialization - AInvest
Iovance Biotherapeutics shares rise 2.03% premarket after UK's MHRA approves Tofersen for rare motor neurone disease. - AInvest
This Beaten-Down Healthcare Stock Could Jump 720%, According to a Wall Street Analyst. Is It Time to Buy? - Yahoo Finance
Iovance Biotherapeutics’ SWOT analysis: stock faces challenges amid promising data - Investing.com
What are the technical indicators suggesting about Iovance Biotherapeutics Inc.Turbocharged investment results - jammulinksnews.com
Does Iovance Biotherapeutics Inc. stock perform well during market downturnsRecord-breaking capital gains - jammulinksnews.com
How Iovance Biotherapeutics Inc. stock performs during market volatilitySwing Entry Risk Mitigation with Chart Analysis - Newser
What are analysts’ price targets for Iovance Biotherapeutics Inc. in the next 12 monthsSkyrocketing profit margins - jammulinksnews.com
Is Iovance Biotherapeutics Inc. Stock a Good Fit for Conservative InvestorsDaily Top Gainers - metal.it
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Shares Acquired by Bank of New York Mellon Corp - Defense World
Levi & Korsinsky Notifies Shareholders of Iovance Biotherapeutics, Inc.(IOVA) of a Class Action Lawsuit and an Upcoming Deadline - Kilgore News Herald
Iovance Biotherapeutics Plummets Amidst Lawsuit and Executive Shake-up - timothysykes.com
Decoding Iovance Biotherapeutics: A TIL Breakout or Premature Optimism? - AInvest
Iovance Biotherapeutics Is Waking UpPrice Action Screams Breakout, But Fundamentals Demand Patience - Seeking Alpha
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) Held Back By Insufficient Growth Even After Shares Climb 75% - 富途牛牛
Iovance Biotherapeutics Soars 13.37% on FDA Approval, Buy Rating - AInvest
What analysts say about Iovance Biotherapeutics Inc. stockUnprecedented market success - PrintWeekIndia
Iovance Biotherapeutics shares rise 5.47% premarket after Pfizer's $1.25 billion licensing agreement for cancer drug. - AInvest
Iovance Biotherapeutics to Host Second Quarter and First - GlobeNewswire
About Us - FinancialContent
Goldman Sachs Downgrade Sends Iovance Biotherapeutics Tumbling - timothysykes.com
Iovance Biotherapeutics Inc (IOVA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.93%
0.15%
자본화:
|
볼륨(24시간):